Cargando…

PB1906: HYPOMETHYLATING AGENT PLUS LOW DOSE VENETOCLAX – A CHEMOTHERAPY-FREE INDUCTION OF ACUTE MYELOID LEUKEMIA TO ACHIEVE COMPLETE REMISSION IN PATIENTS UNFIT FOR CHEMOTHERAPY

Detalles Bibliográficos
Autores principales:	Kumar, Karthik, Singh, Sashi Kant, Nayak, Jhasaketan, Gupta, Adamya, Satadeve, Paras, Kavya, Ronanki, Singh, Pratibha, Muralidharan, Aishwarya, K, Arjun, Benson, Reshma, Dhingra, Gaurav, Nath, Uttam Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430072/ http://dx.doi.org/10.1097/01.HS9.0000974448.45321.57

Ejemplares similares

P400: COMPARISON OF MORPHOLOGICAL & MRD RESPONSE WITH DEXAMETHASONE VERSUS PREDNISOLONE IN BFM 2009 INDUCTION THERAPY IN PEDIATRIC AND AYA ACUTE LYMPHOBLASTIC LEUKEMIA: A SINGLE-CENTER STUDY FROM INDIA
por: Kumar, Karthik, et al.
Publicado: (2023)

PB1860: HIGH EFFICACY OF HYPOMETHYLATING AGENTS PLUS VENETOCLAX COMBINATION THERAPY IN ELDERLY PATIENTS AML PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY: A REAL-LIFE EXPERIENCE.
por: Zannier, Maria Elena, et al.
Publicado: (2023)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

PB1886: REAL WORLD EXPERIENCE OF VENETOCLAX-AZACYTIDINE COMBINATION IN FRAIL ELDERLY PATIENTS UNFIT FOR INTENSIVE CHEMOTHERAPY
por: Rahimi, Muhammad Naim Bin Che, et al.
Publicado: (2023)

Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
por: Zhang, Keyuan, et al.
Publicado: (2023)

Perspectives of caregivers of older adults with acute myeloid leukemia during initial hypomethylating agents and venetoclax chemotherapy
por: Tan, Kelly R., et al.
Publicado: (2023)

Hepatic Plasmacytoma With DEL13q14 Positive on Fluorescent In Situ Hybridization (FISH) on Tissue Biopsy
por: Kumar, Karthik, et al.
Publicado: (2022)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

MRD negative CR after azacitidine and venetoclax in a young patient with AML, unfit for intensive induction followed by ASCT
por: Shukla, Deepak Kumar, et al.
Publicado: (2021)

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
por: Pratz, Keith W., et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Helical tomotherapy for asymptomatic chemotherapy-refractory or -unfit multiple (3 or more) metastases
por: Yamada, Yuki, et al.
Publicado: (2022)

The Unfit
por: Sinclair, W. J. H.
Publicado: (1911)

The Unfit
Publicado: (1911)

Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience
por: Roldán Pérez, Alicia, et al.
Publicado: (2022)

Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy
por: Marín-Jiménez, Juan A., et al.
Publicado: (2022)

The successful combination of grapefruit juice and venetoclax in an unfit acute myeloid leukemia patient with adverse risk: A case report
por: Long, Zhangbiao, et al.
Publicado: (2022)

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML
por: Chen, Xiaotong, et al.
Publicado: (2023)

CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy
por: Bankur, Mustafa Nissar, et al.
Publicado: (2022)

Hypomethylating agents synergize with irinotecan to improve response to chemotherapy in colorectal cancer cells
por: Sharma, Anup, et al.
Publicado: (2017)

Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy
por: Singh, Ratnakar, et al.
Publicado: (2021)

The Marriage of the Unfit
Publicado: (1898)

The Sterilsation of the Unfit
Publicado: (1913)

Sterilization of the Unfit
por: Bristowe, H. C.
Publicado: (1931)

National "Unfits"
Publicado: (1920)

Multiplication of the Unfit
Publicado: (1921)

Asexualization of the Unfit
Publicado: (1912)

The Marriage of the Unfit
por: Campbell, Harry
Publicado: (1898)

Sterilization of the Unfit
por: Bogart, G. Henri
Publicado: (1912)

Sterilizing the Unfit
por: Bogart, G. Henri
Publicado: (1912)

Sterilization of the Unfit
por: Bogart, G. Henri
Publicado: (1910)

Asexualization of the Unfit
Publicado: (1912)

Sterilizing the Unfit
por: Bogart, G. Henri
Publicado: (1913)

PB1857: VENETOCLAX, AZACITIDINE, COMBINED WITH LOW-DOSE CYTARABINE IN OLDERLY OR UNFIT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
por: Han, Xiao, et al.
Publicado: (2023)

AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax
por: Low, Soon Khai, et al.
Publicado: (2022)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
por: Hu, Xiaoyan, et al.
Publicado: (2023)

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
por: Johnson, Isla M., et al.
Publicado: (2022)

Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis
por: Ye, Fanghua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9lvbd2k92kg93jph99t242blkj